NASDAQ : BRVE
Braveheart Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 21.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.73B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Details
| Name | Braveheart Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 49 |
| Founded | 2024 |
| Ipo Date | 2026-08-06 |
| Ceo | Travis Murdoch |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US10567X1019 |
| Cusip | 10567X101 |
| Cik | 2131524 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Travis Murdoch B.S., M.D., M.Sc. | Chief Executive Officer, President and Director |
| James Paul Rickey CPA | Chief Financial Officer |
| Michele A. Anderson | Chief Development Officer |
| Marc Evanchik M.S. | Chief Scientific Officer |
| Natalie Dement J.D. | Vice President and Head of Legal |
| Timothy Y. Zhou | Director of Corporate Development |
| Steph Palencia | Associate Director of Human Resources and Office Manager |
| Brittany de Temple | Senior Vice President of Development Operations |
| Dr. Emil M. deGoma M.D. | Chief Medical Officer |
| Tyler Chavez Ph.D. | Chief Business Officer |
Contact
| Address | One Letterman Drive, Building A, San Francisco, California 94129, United States |
| Phone | 415 707 6312 |
| Website | https://www.braveheart.bio |